Blood Samples Collected to Study a Blood Test for Cancer
Collects blood from healthy adults and people with cancer or liver disease.
Plain-language title generated from the registry record
Registry title: Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
Key facts
- Where
- Coon Rapids, Dallas, Fridley, Memphis, Minneapolis, Redondo Beach, and Richardson, United StatesSee the 7 sites
Where in United States
- Allina Health, Virginia Piper Cancer InstituteCoon Rapids, United StatesTaking people
- Liver Center of TexasDallas, United StatesTaking people
- Virginia Piper Cancer Institute Mercy Hospital-Unity CampusFridley, United StatesTaking people
- Methodist LeBonheur HealthcareMemphis, United StatesTaking people
- VPCI Oncology ResearchMinneapolis, United StatesTaking people
- Torrance Memorial Physician Network - Cancer CareRedondo Beach, United StatesNo longer taking part
- Methodist HospitalRichardson, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Helio Genomics
- Trial code
- NCT05181826
- Record updated
- 10 July 2026
- Original description
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.Read full original descriptionShow less
Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer
To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benign conditions that may induce false positive or false negative results, and iii) defining the effects of potential interfering substances, such as chemotherapy drugs.
Inclusion: 2.1.1 Age 18 years or older; 2.1.2 A diagnosis of cancer, cancer remission, benign disease (benign tumor, diabetes, liver cirrhosis, chronic hepatitis B or hepatitis C virus infection, Chronic obstructive pulmonary disease, etc.) or apparently healthy volunteers. .
Exclusion: 2.2.1 Patients that are unwilling or unable to sign the Informed Consent Form will be excluded; 2.2.2 Approximately 50 mL of blood will be drawn from participants within an 8-week period under this protocol. Patients that have already given 50 mL of blood within this time frame will be excluded.